The essential and potentially inappropriate use of antipsychotics across income groups: An analysis of linked administrative data

Canadian Journal of Psychiatry

Volumn 57, Issue 8, 2012, Pages 488-495

  Puyat, Joseph H ^a   Law, Michael R ^a   Wong, Sabrina T ^a   Sutherland, Jason M ^a   Morgan, Steven G ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Adult; Antipsychotic; Dementia; Disparity; Essential use; Income; Potentially inappropriate use; Schizophrenia; Seniors

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; AGED; ARTICLE; BIPOLAR DISORDER; COHORT ANALYSIS; DEMENTIA; DRUG MISUSE; FEMALE; HEALTH ECONOMICS; HUMAN; LONG TERM CARE; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; MALE; PREVALENCE; SCHIZOPHRENIA; TREATMENT DURATION;

EID: 84873051356     PISSN: 07067437     EISSN: 14970015     Source Type: Journal    
DOI: 10.1177/070674371205700807     Document Type: Article

References (27)

1. World Health Organization (WHO). WHO model lists of essential medicines. Geneva (CH): WHO; 2010.
2. Canadian Psychiatric Association. Clinical practice guidelines. Treatment of schizophrenia. Can J Psychiatry. 2005;50(13 Suppl 1):7S-57S.
3. American Psychiatric Association (APA). APA practice guidelines for the treatment of psychiatric disorders: comprehensive guidelines and guideline watches. 2nd ed. Arlington (VA): APA; 2004.
4. Shekelle P, Maglione M, Bagley S, et al. Efficacy and comparative effectiveness of off-label use of atypical antipsychotics. Rockville (MD): Agency for Healthcare Research and Quality; 2007.
5. Ballard C, Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database Syst Rev. 2006;(1):1-128.
6. Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006;14(3):191-210.
7. Schneider LS, Dagerman KS, Insel PS. Risk of death with atypical antipsychotic drug treatment for dementia. JAMA. 2005;294(15):1934-1943.
8. Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med. 2006;355(15):1525-1538.
9. Valiyeva E, Herrmann N, Rochon PA, et al. Effect of regulatory warnings on antipsychotic prescription rates among elderly patients with dementia: a population-based time-series analysis. CMAJ. 2008;179(5):438-446.
10. Canadian Institute for Health Information (CIHI). Antipsychotic use in seniors: an analysis focusing on drug claims, 2001 to 2007. Ottawa (ON): CIHI; 2009. p 23.
11. Alshammari AM, Hux JE. The impact of non-fee-for-service reimbursement on chronic disease surveillance using administrative data. Can J Public Health. 2010;100(6):472-474.
12. Howard R. Late-onset schizophrenia and very-late-onset schizophrenia-like psychosis: an international consensus. Am J Psychiatry. 2000;157(2):172-178.
13. Lurie N, Popkin M, Dysken M, et al. Accuracy of diagnoses of schizophrenia in Medicaid claims. Hosp Community Psychiatry. 1992;43(1):69-71.
14. Anon. Canadian study of health and aging: study methods and prevalence of dementia. CMAJ. 1994;150(6):899-913.
15. Yatham LN, Kennedy SH, O'Donovan C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord. 2005;7(Suppl 3):5-69.
16. Pippenger M, Holloway RG, Vickrey BG. Neurologists' use of ICD-9CM codes for dementia. Neurology. 2001;56(9):1206-1209.
17. World Health Organization (WHO) Collaborating Centre for Drug Statistics Methodology. Antipsychotics. WHOCC-ATC/DDD Index [Internet]. Geneva (CH): WHO; 2009 [cited 2012 May 22]. Available from: http://www.whocc.no/atc-ddd-index/? code=N05A&showdescription=yes.
18. Sultzer DL, Davis SM, Tariot PN, et al. Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry. 2008;165(7):844-854.
19. Hanley GE, Morgan S. On the validity of area-based income measures to proxy household income. BMC Health Serv Res. 2008;8(1):79.
20. Hanley GE, Morgan S, Reid RJ. Explaining prescription drug use and expenditures using the adjusted clinical groups case-mix system in the population of British Columbia, Canada. Med Care. 2010;48(5):402-408.
21. Andersen R, Newman JF. Societal and individual determinants of medical care utilization in the United States. Milbank Mem Fund Q Health Soc. 1973;51(1):95-124.
22. StataCorp. Stata statistical software: release 10. College Station (TX): StataCorp LP; 2007.
23. Voyer P, Verreault R, Azizah GM, et al. Prevalence of physical and verbal aggressive behaviours and associated factors among older adults in long-term care facilities. BMC Geriatr. 2005;5:13.
24. Aupperle P. Management of aggression, agitation, and psychosis in dementia: focus on atypical antipsychotics. Am J Alzheimers Dis Other Demen. 2006;21(2):101-108.
25. Guidelines and Protocols Advisory Committee. Cognitive impairment in the elderly-recognition, diagnosis and management [Internet]. Victoria (BC): British Columbia Ministry of Health; 2007 Jul 15 [updated 2008 Jan 30; cited 2012 Jan 26]. Available from: http://www.bcguidelines.ca/guideline-cognitive.html. Jointly published by the British Columbia Medical Association.
26. Rochon PA. Exploring the variation in Ontario nursing home prescribing rates for antipsychotics. Healthc Q. 2007;10(4):20-22.
27. British Columbia Ministry of Health. A review of the use of antipsychotic drugs in British Columbia residential care facilities [Internet]. Victoria (BC): Ministry of Health; 2011 Dec [cited 2012 Jan 20]. Available from: http://www.health.gov.bc.ca/library/publications/year/2011/use-of-antipsychotic- drugs.pdf.